BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Antibody-mediated protection against Ebola virus. Nat Immunol 2018;19:1169-78. [PMID: 30333617 DOI: 10.1038/s41590-018-0233-9] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 17.8] [Reference Citation Analysis]
Number Citing Articles
1 Lukosaityte D, Sadeyen JR, Shrestha A, Sealy JE, Bhat S, Chang P, Digard P, Iqbal M. Engineered Recombinant Single Chain Variable Fragment of Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian Influenza. Vaccines (Basel) 2020;8:E118. [PMID: 32138253 DOI: 10.3390/vaccines8010118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cohen-dvashi H, Zehner M, Ehrhardt S, Katz M, Elad N, Klein F, Diskin R. Structural Basis for a Convergent Immune Response against Ebola Virus. Cell Host & Microbe 2020;27:418-427.e4. [DOI: 10.1016/j.chom.2020.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
3 Gu C, Cao X, Wang Z, Hu X, Yao Y, Zhou Y, Liu P, Liu X, Gao G, Hu X, Zhang Y, Chen Z, Gao L, Peng Y, Jia F, Shan C, Yu L, Liu K, Li N, Guo W, Jiang G, Min J, Zhang J, Yang L, Shi M, Hou T, Li Y, Liang W, Lu G, Yang C, Wang Y, Xia K, Xiao Z, Xue J, Huang X, Chen X, Ma H, Song D, Pan Z, Wang X, Guo H, Liang H, Yuan Z, Guan W, Deng SJ. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. MAbs 2021;13:1930636. [PMID: 34097570 DOI: 10.1080/19420862.2021.1930636] [Reference Citation Analysis]
4 Gunn BM, Lu R, Slein MD, Ilinykh PA, Huang K, Atyeo C, Schendel SL, Kim J, Cain C, Roy V, Suscovich TJ, Takada A, Halfmann PJ, Kawaoka Y, Pauthner MG, Momoh M, Goba A, Kanneh L, Andersen KG, Schieffelin JS, Grant D, Garry RF, Saphire EO, Bukreyev A, Alter G. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity 2021;54:815-828.e5. [PMID: 33852832 DOI: 10.1016/j.immuni.2021.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 McMullan LK, Flint M, Chakrabarti A, Guerrero L, Lo MK, Porter D, Nichol ST, Spiropoulou CF, Albariño C. Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis. Lancet Infect Dis 2019;19:1023-32. [PMID: 31300330 DOI: 10.1016/S1473-3099(19)30291-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 9.7] [Reference Citation Analysis]
6 Ullah MA, Sarkar B, Islam SS. Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus. Immunobiology 2020;225:151949. [PMID: 32444135 DOI: 10.1016/j.imbio.2020.151949] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
7 Ray K, Mengistu M, Orlandi C, Pazgier M, Lewis GK, DeVico AL. Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure. Front Immunol 2019;10:1512. [PMID: 31338095 DOI: 10.3389/fimmu.2019.01512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Ndungo E. mSphere of Influence: Learning from Nature-Antibody Profiles Important for Protection of Young Infants. mSphere 2020;5:e01021-20. [PMID: 33055264 DOI: 10.1128/mSphere.01021-20] [Reference Citation Analysis]
9 Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251. [PMID: 32366817 DOI: 10.1038/s41467-020-16256-y] [Cited by in Crossref: 475] [Cited by in F6Publishing: 450] [Article Influence: 237.5] [Reference Citation Analysis]
10 Kombe Kombe AJ, Zahid A, Mohammed A, Shi R, Jin T. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Front Mol Biosci 2021;8:670815. [PMID: 34136533 DOI: 10.3389/fmolb.2021.670815] [Reference Citation Analysis]
11 Hashem AM, Algaissi A, Almahboub SA, Alfaleh MA, Abujamel TS, Alamri SS, Alluhaybi KA, Hobani HI, AlHarbi RH, Alsulaiman RM, ElAssouli MZ, Hala S, Alharbi NK, Alhabbab RY, AlSaieedi AA, Abdulaal WH, Bukhari A, Al-Somali AA, Alofi FS, Khogeer AA, Pain A, Alkayyal AA, Almontashiri NAM, Ahmad BM, Li X. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients.Viruses. 2020;12. [PMID: 33291713 DOI: 10.1101/2020.09.21.20198309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Goodarzi P, Mahdavi F, Mirzaei R, Hasanvand H, Sholeh M, Zamani F, Sohrabi M, Tabibzadeh A, Jeda AS, Niya MHK, Keyvani H, Karampoor S. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. Int Immunopharmacol 2020;88:106885. [PMID: 32795893 DOI: 10.1016/j.intimp.2020.106885] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
13 Laing E, Sterling S, Richard S, Epsi N, Phogat S, Samuels E, Yan L, Moreno N, Coles C, Drew M, Mehalko J, English C, Merritt S, Mende K, Chung K, Clifton G, Munster V, de Wit E, Tribble D, Agan B, Esposito D, Lanteri C, Mitre E, Burgess T, Broder C. A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and antibody cross reactions. Res Sq 2020:rs. [PMID: 33269345 DOI: 10.21203/rs.3.rs-105768/v1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev 2022. [PMID: 35661178 DOI: 10.1111/imr.13091] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Meyer M, Gunn BM, Malherbe DC, Gangavarapu K, Yoshida A, Pietzsch C, Kuzmina NA, Saphire EO, Collins PL, Crowe JE Jr, Zhu JJ, Suchard MA, Brining DL, Mire CE, Cross RW, Geisbert JB, Samal SK, Andersen KG, Alter G, Geisbert TW, Bukreyev A. Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Sci Transl Med 2021;13:eabg6128. [PMID: 34261800 DOI: 10.1126/scitranslmed.abg6128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hargreaves A, Brady C, Mellors J, Tipton T, Carroll MW, Longet S. Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. Pathogens 2021;10:1201. [PMID: 34578233 DOI: 10.3390/pathogens10091201] [Reference Citation Analysis]
17 Valle C, Martin B, Debart F, Vasseur JJ, Imbert I, Canard B, Coutard B, Decroly E. The C-Terminal Domain of the Sudan Ebolavirus L Protein Is Essential for RNA Binding and Methylation. J Virol 2020;94:e00520-20. [PMID: 32269120 DOI: 10.1128/JVI.00520-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zhou X, Ma F, Xie J, Yuan M, Li Y, Shaabani N, Zhao F, Huang D, Wu NC, Lee CD, Liu H, Li J, Chen Z, Hong Y, Liu WH, Xiao N, Burton DR, Tu H, Li H, Chen X, Teijaro JR, Wilson IA, Xiao C, Huang Z. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Rep 2021;35:109109. [PMID: 33932326 DOI: 10.1016/j.celrep.2021.109109] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Amanat F, Strohmeier S, Meade P, Dambrauskas N, Mühlemann B, Smith DJ, Vigdorovich V, Sather DN, Coughlan L, Krammer F. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biol 2021;19:e3001384. [PMID: 34914685 DOI: 10.1371/journal.pbio.3001384] [Reference Citation Analysis]
20 Wagstaffe HR, Clutterbuck EA, Bockstal V, Stoop JN, Luhn K, Douoguih M, Shukarev G, Snape MD, Pollard AJ, Riley EM, Goodier MR. Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination. J Infect Dis 2021;223:1171-82. [PMID: 31821493 DOI: 10.1093/infdis/jiz657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Carreño JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, Gonzalez-Reiche AS, van de Guchte A, Study Group P, Srivastava K, Sordillo EM, Sather DN, van Bakel H, Krammer F, Simon V. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. EBioMedicine 2021;73:103626. [PMID: 34688034 DOI: 10.1016/j.ebiom.2021.103626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun 2020;11:4303. [PMID: 32855401 DOI: 10.1038/s41467-020-18159-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 36.5] [Reference Citation Analysis]
23 Gunn BM, Bai S. Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Hum Vaccin Immunother 2021;:1-17. [PMID: 34613865 DOI: 10.1080/21645515.2021.1976580] [Reference Citation Analysis]
24 Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020;369:1010-4. [PMID: 32540901 DOI: 10.1126/science.abd0827] [Cited by in Crossref: 453] [Cited by in F6Publishing: 420] [Article Influence: 226.5] [Reference Citation Analysis]
25 [DOI: 10.1101/2020.07.14.20151126] [Cited by in Crossref: 82] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
26 Valgardsdottir R, Cattaneo I, Napolitano G, Raglio A, Spinelli O, Salmoiraghi S, Castilletti C, Lapa D, Capobianchi MR, Farina C, Golay J. Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization. Antibodies (Basel) 2021;10:26. [PMID: 34287229 DOI: 10.3390/antib10030026] [Reference Citation Analysis]
27 Gunn BM, Roy V, Karim MM, Hartnett JN, Suscovich TJ, Goba A, Momoh M, Sandi JD, Kanneh L, Andersen KG, Shaffer JG, Schieffelin JS, Garry RF, Grant DS, Alter G. Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses. J Infect Dis 2020;221:156-61. [PMID: 31301137 DOI: 10.1093/infdis/jiz364] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
28 Wassenaar TM, Wanchai V, Buzard GS, Ussery DW. In silico Selection of Amplification Targets for Rapid Polymorphism Screening in Ebola Virus Outbreaks. Front Microbiol 2019;10:857. [PMID: 31080442 DOI: 10.3389/fmicb.2019.00857] [Reference Citation Analysis]
29 Irvine EB, Alter G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology 2020;30:241-53. [PMID: 32103252 DOI: 10.1093/glycob/cwaa018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
30 Parzych EM, Gulati S, Zheng B, Bah MA, Elliott STC, Chu JD, Nowak N, Reed GW, Beurskens FJ, Schuurman J, Rice PA, Weiner DB, Ram S. Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection. mBio 2021;12:e00242-21. [PMID: 33727348 DOI: 10.1128/mBio.00242-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Edwardson TGW, Hilvert D. Virus-Inspired Function in Engineered Protein Cages. J Am Chem Soc 2019;141:9432-43. [PMID: 31117660 DOI: 10.1021/jacs.9b03705] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
32 Mor M, Werbner M, Alter J, Safra M, Chomsky E, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Shalom NB, Navon M, Rafael D, Sharim H, Kiner E, Griffis E, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dassau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT. Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors. bioRxiv 2020:2020. [PMID: 33052341 DOI: 10.1101/2020.10.06.323634] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Yeh YT, Gulino K, Zhang Y, Sabestien A, Chou TW, Zhou B, Lin Z, Albert I, Lu H, Swaminathan V, Ghedin E, Terrones M. A rapid and label-free platform for virus capture and identification from clinical samples. Proc Natl Acad Sci U S A 2020;117:895-901. [PMID: 31882450 DOI: 10.1073/pnas.1910113117] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 20.3] [Reference Citation Analysis]
34 Miller NL, Raman R, Clark T, Sasisekharan R. Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies. Front Immunol 2022;13:904609. [DOI: 10.3389/fimmu.2022.904609] [Reference Citation Analysis]
35 Culos A, Tsai AS, Stanley N, Becker M, Ghaemi MS, McIlwain DR, Fallahzadeh R, Tanada A, Nassar H, Espinosa C, Xenochristou M, Ganio E, Peterson L, Han X, Stelzer IA, Ando K, Gaudilliere D, Phongpreecha T, Marić I, Chang AL, Shaw GM, Stevenson DK, Bendall S, Davis KL, Fantl W, Nolan GP, Hastie T, Tibshirani R, Angst MS, Gaudilliere B, Aghaeepour N. Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions. Nat Mach Intell 2020;2:619-28. [PMID: 33294774 DOI: 10.1038/s42256-020-00232-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
36 Wang S, Peng Y, Wang R, Jiao S, Wang M, Huang W, Shan C, Jiang W, Li Z, Gu C, Chen B, Hu X, Yao Y, Min J, Zhang H, Chen Y, Gao G, Tang P, Li G, Wang A, Wang L, Zhang J, Chen S, Gui X, Yuan Z, Liu D. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun 2020;11:5752. [PMID: 33188207 DOI: 10.1038/s41467-020-19568-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 8.5] [Reference Citation Analysis]
37 Butler AL, Fallon JK, Alter G. A Sample-Sparing Multiplexed ADCP Assay. Front Immunol 2019;10:1851. [PMID: 31456799 DOI: 10.3389/fimmu.2019.01851] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
38 Hong J, Zhong L, Zheng Q, Wu Q, Zha Z, Wei D, Chen H, Zhang W, Zhang S, Huang Y, Chen K, Chen J, Li S, Zeng MS, Zeng YX, Xia N, Zhang X, Xu M, Chen Y. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge In Vivo. J Virol 2022;:e0007522. [PMID: 35348362 DOI: 10.1128/jvi.00075-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 [DOI: 10.1101/2020.05.19.104281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Cartwright HN, Barbeau DJ, McElroy AK. Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo. mSphere 2021;6:e0055621. [PMID: 34494884 DOI: 10.1128/mSphere.00556-21] [Reference Citation Analysis]
41 Fedry J, Hurdiss DL, Wang C, Li W, Obal G, Drulyte I, Du W, Howes SC, van Kuppeveld FJM, Förster F, Bosch BJ. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci Adv 2021;7:eabf5632. [PMID: 33958322 DOI: 10.1126/sciadv.abf5632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, Crowe JE Jr, Ward AB. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Rep 2021;35:108984. [PMID: 33852862 DOI: 10.1016/j.celrep.2021.108984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Junaid A, Tang H, van Reeuwijk A, Abouleila Y, Wuelfroth P, van Duinen V, Stam W, van Zonneveld AJ, Hankemeier T, Mashaghi A. Ebola Hemorrhagic Shock Syndrome-on-a-Chip. iScience 2020;23:100765. [PMID: 31887664 DOI: 10.1016/j.isci.2019.100765] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
44 Tyagi A, Nigam S, Chauhan RS. A Concise Review of Baseline Facts of SARS‐CoV‐2 for Interdisciplinary Research. ChemistrySelect 2020;5:10897-923. [DOI: 10.1002/slct.202002420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zhou X, Li Z, Zhang Z, Zhu L, Liu Q. A rapid and label-free platform for virus enrichment based on electrostatic microfluidics. Talanta 2021;242:122989. [PMID: 35189409 DOI: 10.1016/j.talanta.2021.122989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Misasi J, Sullivan NJ. Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. Immunity 2021;54:412-36. [PMID: 33691133 DOI: 10.1016/j.immuni.2021.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Duehr J, McMahon M, Williamson B, Amanat F, Durbin A, Hawman DW, Noack D, Uhl S, Tan GS, Feldmann H, Krammer F. Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model. mBio 2020;11:e00028-20. [PMID: 32209676 DOI: 10.1128/mBio.00028-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
48 Hashem AM, Algaissi A, Almahboub SA, Alfaleh MA, Abujamel TS, Alamri SS, Alluhaybi KA, Hobani HI, AlHarbi RH, Alsulaiman RM, ElAssouli MZ, Hala S, Alharbi NK, Alhabbab RY, AlSaieedi AA, Abdulaal WH, Bukhari A, Al-Somali AA, Alofi FS, Khogeer AA, Pain A, Alkayyal AA, Almontashiri NAM, Ahmad BM, Li X. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses 2020;12:E1390. [PMID: 33291713 DOI: 10.3390/v12121390] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
49 Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity 2020;53:524-532.e4. [PMID: 32783920 DOI: 10.1016/j.immuni.2020.07.020] [Cited by in Crossref: 158] [Cited by in F6Publishing: 141] [Article Influence: 79.0] [Reference Citation Analysis]
50 Heiss K, Heidepriem J, Fischer N, Weber LK, Dahlke C, Jaenisch T, Loeffler FF. Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays. J Proteome Res 2020;19:4339-54. [PMID: 32892628 DOI: 10.1021/acs.jproteome.0c00484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi A. Recent Advances in Passive Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical Trials. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108786] [Reference Citation Analysis]
52 Garrett ME, Galloway J, Chu HY, Itell HL, Stoddard CI, Wolf CR, Logue JK, McDonald D, Matsen FA 4th, Overbaugh J. High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. bioRxiv 2020:2020. [PMID: 33236010 DOI: 10.1101/2020.11.16.385278] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
53 Laing ED, Sterling SL, Richard SA, Phogat S, Samuels EC, Epsi NJ, Yan L, Moreno N, Coles C, Mehalko J, Drew M, English C, Chung KK, Clifton GT, Munster V, de Wit E, Tribble D, Agan B, Esposito D, Lanteri C, Mitre E, Burgess TH, Broder CC. A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and controls for pre-existing seasonal human coronavirus antibody cross-reactivity. medRxiv 2020:2020. [PMID: 33083807 DOI: 10.1101/2020.10.14.20207050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses 2019;11:E326. [PMID: 30987343 DOI: 10.3390/v11040326] [Cited by in Crossref: 277] [Cited by in F6Publishing: 242] [Article Influence: 92.3] [Reference Citation Analysis]
55 Burton DR. Antibody barriers to going viral. J Exp Med 2019;216:2226-8. [PMID: 31444247 DOI: 10.1084/jem.20191099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Anand SP, Finzi A. Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. Vaccines (Basel) 2019;7:E103. [PMID: 31480293 DOI: 10.3390/vaccines7030103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
57 [DOI: 10.1101/2020.03.11.987958] [Cited by in Crossref: 50] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
58 Mouquet H. MARVellous Sidekick Antibodies. Cell Host Microbe 2020;27:856-8. [PMID: 32526181 DOI: 10.1016/j.chom.2020.05.018] [Reference Citation Analysis]
59 Lee P, Kim CU, Seo SH, Kim DJ. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Netw 2021;21:e4. [PMID: 33728097 DOI: 10.4110/in.2021.21.e4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
60 Levi-Schaffer F, de Marco A. Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31. Br J Pharmacol 2021;178:3359-72. [PMID: 33401333 DOI: 10.1111/bph.15359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Idso MN, Akhade AS, Arrieta-Ortiz ML, Lai BT, Srinivas V, Hopkins JP Jr, Gomes AO, Subramanian N, Baliga N, Heath JR. Antibody-recruiting protein-catalyzed capture agents to combat antibiotic-resistant bacteria. Chem Sci 2020;11:3054-67. [PMID: 34122810 DOI: 10.1039/c9sc04842a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
62 Chromikova V, Tan J, Aslam S, Rajabhathor A, Bermudez-Gonzalez M, Ayllon J, Simon V, García-Sastre A, Salaun B, Nachbagauer R, Krammer F. Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. Vaccine 2020;38:1953-61. [PMID: 31959425 DOI: 10.1016/j.vaccine.2020.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
63 Chen Z, Du R, Galvan Achi JM, Rong L, Cui Q. SARS-CoV-2 cell entry and targeted antiviral development. Acta Pharm Sin B 2021;11:3879-88. [PMID: 34002130 DOI: 10.1016/j.apsb.2021.05.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
64 Fausther-bovendo H, Kobinger G. The road to effective and accessible antibody therapies against Ebola virus. Current Opinion in Virology 2022;54:101210. [DOI: 10.1016/j.coviro.2022.101210] [Reference Citation Analysis]
65 Cai Y, Yu S, Chi X, Radoshitzky SR, Kuhn JH, Berger EA. An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells. PLoS One 2021;16:e0245024. [PMID: 33411835 DOI: 10.1371/journal.pone.0245024] [Reference Citation Analysis]
66 Garrett ME, Galloway J, Chu HY, Itell HL, Stoddard CI, Wolf CR, Logue JK, McDonald D, Weight H, Matsen FA 4th, Overbaugh J. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. Cell 2021;184:2927-2938.e11. [PMID: 34010620 DOI: 10.1016/j.cell.2021.04.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Zhang Y, Wei Y, Li Y, Wang X, Liu Y, Tian D, Jia X, Gong R, Liu W, Yang L. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. PLoS Negl Trop Dis 2021;15:e0008403. [PMID: 33711011 DOI: 10.1371/journal.pntd.0008403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
68 Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Viruses 2021;13:2106. [PMID: 34696536 DOI: 10.3390/v13102106] [Reference Citation Analysis]
69 Stoddard CI, Galloway J, Chu HY, Shipley MM, Sung K, Itell HL, Wolf CR, Logue JK, Magedson A, Garrett ME, Crawford KHD, Laserson U, Matsen FA 4th, Overbaugh J. Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. Cell Rep 2021;35:109164. [PMID: 33991511 DOI: 10.1016/j.celrep.2021.109164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
70 Mccann N, O’connor D, Lambe T, Pollard AJ. Viral vector vaccines. Current Opinion in Immunology 2022;77:102210. [DOI: 10.1016/j.coi.2022.102210] [Reference Citation Analysis]
71 Zhu QY, Shan S, Yu J, Peng SY, Sun C, Zuo Y, Zhong LY, Yan SM, Zhang X, Yang Z, Peng YJ, Shi X, Cao SM, Wang X, Zeng MS, Zhang L. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Nat Commun 2021;12:6624. [PMID: 34785638 DOI: 10.1038/s41467-021-26912-6] [Reference Citation Analysis]
72 Mark JKK, Lim CSY, Nordin F, Tye GJ. Expression of mammalian proteins for diagnostics and therapeutics: a review. Mol Biol Rep. [DOI: 10.1007/s11033-022-07651-3] [Reference Citation Analysis]
73 Haas P, Muralidharan M, Krogan NJ, Kaake RM, Hüttenhain R. Proteomic Approaches to Study SARS-CoV-2 Biology and COVID-19 Pathology. J Proteome Res 2021;20:1133-52. [PMID: 33464917 DOI: 10.1021/acs.jproteome.0c00764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
74 Liu Y, Sun B, Pan J, Feng Y, Ye W, Xu J, Lan M, Sun H, Zhang X, Sun Y, Yang S, Shi J, Zhang F, Cheng L, Jiang D, Yang K. Construction and evaluation of DNA vaccine encoding Ebola virus glycoprotein fused with lysosome-associated membrane protein. Antiviral Res 2021;193:105141. [PMID: 34274417 DOI: 10.1016/j.antiviral.2021.105141] [Reference Citation Analysis]
75 Patel JS, Quates CJ, Johnson EL, Ytreberg FM. Expanding the watch list for potential Ebola virus antibody escape mutations. PLoS One 2019;14:e0211093. [PMID: 30897171 DOI: 10.1371/journal.pone.0211093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
76 Fischinger S, Cizmeci D, Deng D, Grant SP, Frahm N, McElrath J, Fuchs J, Bart PA, Pantaleo G, Keefer M, O Hahn W, Rouphael N, Churchyard G, Moodie Z, Donastorg Y, Streeck H, Alter G. Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. PLoS Pathog 2021;17:e1010016. [PMID: 34843602 DOI: 10.1371/journal.ppat.1010016] [Reference Citation Analysis]
77 Bohan D, Maury W. Enveloped RNA virus utilization of phosphatidylserine receptors: Advantages of exploiting a conserved, widely available mechanism of entry. PLoS Pathog 2021;17:e1009899. [PMID: 34555126 DOI: 10.1371/journal.ppat.1009899] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Ng KW, Faulkner N, Wrobel AG, Gamblin SJ, Kassiotis G. Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. Semin Immunol 2021;:101507. [PMID: 34716096 DOI: 10.1016/j.smim.2021.101507] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Shyr ZA, Gorshkov K, Chen CZ, Zheng W. Drug Discovery Strategies for SARS-CoV-2. J Pharmacol Exp Ther 2020;375:127-38. [PMID: 32723801 DOI: 10.1124/jpet.120.000123] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 18.5] [Reference Citation Analysis]